Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.
Because long-term survival of patients with nonbulky stage IA to IIA Hodgkin lymphoma is dependent on disease control and avoidance of late toxic effects associated with the treatment received, the initial choice of treatment can be associated with trade-offs that balance optimum disease control with avoidance of these late effect risks. Health professionals and patients face the dilemma of making treatment decisions without the benefit of completely understanding the risk-benefit balances associated with how current treatments affect all outcomes of interest. Optimum management of these patients requires careful multidisciplinary evaluation and communication strategies that account for patient preferences.
['Hay|Annette E|AE|', 'Meyer|Ralph M|RM|']
D000971:Antineoplastic Combined Chemotherapy Protocols D001761:Bleomycin D003131:Combined Modality Therapy D003606:Dacarbazine D003657:Decision Making D004317:Doxorubicin D006689:Hodgkin Disease D006801:Humans D009367:Neoplasm Staging D017410:Practice Guidelines as Topic D018570:Risk Assessment D016896:Treatment Outcome D014747:Vinblastine
Hodgkin lymphoma Chemotherapy Combined modality therapy Radiation therapy Review